TERT and neoplasm: Some articles have reported that the incidence of TERT promoter mutations is approximately 7.5-27% in PTC (37), and the mutation is correlated with particularly aggressive clinicopathological parameters, such as extrathyroidal extension, larger tumor size, and lymph node metastases (38–40).